• Anthony Turpin, Jean-Marie Michot, Emmanuelle Kempf, Renaud Mazeron, Peggy Dartigues, Marie Terroir, Angela Boros, Serge Bonnetier, Cristina Castilla-Llorente, Tereza Coman, Alina Danu, David Ghez, Sylvain Pilorge, Julia Arfi-Rouche, Laurent Dercle, Jean-Charles Soria, Patrice Carde, Vincent Ribrag, Christophe Fermé, and Julien Lazarovici.
• Cancer campus Grand-Paris, Gustave-Roussy cancer comprehensive center, département des innovation thérapeutiques et essais précoces, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Cancer campus Grand-Paris, Gustave-Roussy cancer comprehensive center, département d'hématologie, 114, rue Édouard-Vaillant, 94805 Villejuif, France; CHRU de Lille, service d'oncologie médicale, 59000 Lille, France.
• Bull Cancer. 2018 Jan 1; 105 (1): 81-98.

AbstractHodgkin lymphoma (HL) is a cancer that mostly affects young people, in which modern therapeutic strategies using chemotherapy and radiotherapy result in a cure rate exceeding 80%. Survivors are exposed to long-term consequences of treatments, such as secondary malignancies and cardiovascular diseases, whose mortality exceeds the one of the disease itself, with long-term follow-up. The current therapeutic strategy in HL, based on the assessment of initial risk factors, is the result of large clinical trials led by the main international cooperating groups. More recently, several groups have tried to develop treatment strategies adapted to the response to chemotherapy, evaluated by interim PET/CT scan. However to date, the combined treatment with chemotherapy followed by radiation therapy remains a standard in most of the above-diaphragmatic localized forms. Immune checkpoint inhibitors, and especially anti-PD1 antibodies, have shown dramatic results in some serious forms of relapsed or refractory HL, with limited toxicity, and may contribute in the future to reduce the toxicities of treatments.Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

21 keywords...

hide…